Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 3/20 | 0.63 |
| ▸ | HSP90AA1 | P07900 | 6/20 | 0.58 |
| ▸ | HSP90AB1 | P08238 | 6/20 | 0.58 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.51 |
| ▸ | MGAM | O43451 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | SI | P14410 | 2/20 | 0.50 |
| ▸ | MGAM2 | Q2M2H8 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2819423 | 0.88 | NOTUM (0.68) | HDAC1HSP90AA1HSP90AB1NOTUMCYP19A1 | |
| SCHEMBL2823001 | 0.86 | HDAC1 (0.63) | HDAC1HSP90AB1NOTUMCYP19A1 | |
| SCHEMBL9969547 | 0.84 | HDAC1 (0.61) | HDAC1NOTUMCYP19A1 | |
| SCHEMBL19941362 | 0.81 | NOTUM (0.56) | HDAC1HSP90AB1NOTUMCYP19A1 | |
| SCHEMBL9969765 | 0.75 | TGM2 (0.64) | NOTUMCYP19A1 | |
| SCHEMBL17336980 | 0.74 | HSP90AA1 (0.61) | HDAC1HSP90AA1HSP90AB1 | |
| SCHEMBL14270133 | 0.74 | NOTUM (0.49) | HDAC1HSP90AB1NOTUMCYP19A1 | |
| SCHEMBL2821391 | 0.74 | NOTUM (0.68) | HDAC1HSP90AA1HSP90AB1NOTUMCYP19A1 | |
| SCHEMBL10094367 | 0.74 | HSP90AA1 (0.57) | HDAC1HSP90AA1HSP90AB1NOTUMMGAM | |
| SCHEMBL16219151 | 0.73 | TYR (0.60) | HDAC1HSP90AB1NOTUMCYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-8841263-B2 | Macrocyclic compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2014-09-23 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | SILICON VALLEY BANK | 2012-10-04 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-8202843-B2 | Macrocyclic compounds and methods of making and using the same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-06-19 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | BioVersys AG (CH) | 2008-02-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120252747-A1 | MACROCYCLIC COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | CCNO, PTGDR, CCNE1 | HDAC1 251/4885HSP90AA1 3792/4885HSP90AB1 3737/4885 |
| US-20080045585-A1 | Macrocyclic Compounds And Methods Of Making And Using The Same | VIP, PROKR1, PGC | HDAC1 701/4885HSP90AA1 2101/4885HSP90AB1 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.